Mitral stenosis resident survival guide: Difference between revisions
No edit summary |
No edit summary |
||
Line 15: | Line 15: | ||
*[[Rheumatic fever]]<ref name="Tadele-2013">{{Cite journal | last1 = Tadele | first1 = H. | last2 = Mekonnen | first2 = W. | last3 = Tefera | first3 = E. | title = Rheumatic mitral stenosis in Children: more accelerated course in sub-Saharan Patients. | journal = BMC Cardiovasc Disord | volume = 13 | issue = 1 | pages = 95 | month = Nov | year = 2013 | doi = 10.1186/1471-2261-13-95 | PMID = 24180350 }}</ref> | *[[Rheumatic fever]]<ref name="Tadele-2013">{{Cite journal | last1 = Tadele | first1 = H. | last2 = Mekonnen | first2 = W. | last3 = Tefera | first3 = E. | title = Rheumatic mitral stenosis in Children: more accelerated course in sub-Saharan Patients. | journal = BMC Cardiovasc Disord | volume = 13 | issue = 1 | pages = 95 | month = Nov | year = 2013 | doi = 10.1186/1471-2261-13-95 | PMID = 24180350 }}</ref> | ||
==Initial Evaluation== | ==Initial Evaluation== | ||
Shown below is an algorithm summarizing the approach to < | Shown below is an algorithm summarizing the approach to the initial evluation of mitral stenosis according to 2014 AHA/ACC guidelines for management of valvular heart disease.<ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume= | issue= | pages= | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852 }} </ref>. | ||
{{familytree/start |summary=PE diagnosis Algorithm.}} | {{familytree/start |summary=PE diagnosis Algorithm.}} | ||
{{familytree | | A01 |A01=<div style="float: left; text-align: left; width: 26em; padding:1em;"> '''Characterize the symptoms:'''<br> | {{familytree | | A01 |A01=<div style="float: left; text-align: left; width: 26em; padding:1em;"> '''Characterize the symptoms:'''<br> | ||
Line 66: | Line 66: | ||
❑ Disease of other valves <br> | ❑ Disease of other valves <br> | ||
❑ Left ventricular function<br> | ❑ Left ventricular function<br> | ||
❑ Suitability of valve morphology for [[PMBC]]<br> </div>}} | ❑ Suitability of valve morphology for [[PMBV|PMBC]]<br> </div>}} | ||
{{familytree | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | {{familytree | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | ||
{{familytree | | F01 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |F01=<div style="float: left; text-align: left; width: 26em; padding:1em;"> '''Medical therapy'''<br> | {{familytree | | F01 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |F01=<div style="float: left; text-align: left; width: 26em; padding:1em;"> '''Medical therapy'''<br> | ||
❑ Consider heart rate control in [[MS]] patients with:<br> | ❑ Consider [[Atrial fibrillation resident survival guide#Heart rate control|heart rate control]] in [[MS]] patients with:<br> | ||
: ❑ Normal [[sinus rhythm]] and symptoms present on exercise<br> | : ❑ Normal [[sinus rhythm]] and symptoms present on exercise<br> | ||
: ❑ [[AF]] and fast ventricular response<br> | : ❑ [[AF]] and fast ventricular response<br> | ||
Line 78: | Line 78: | ||
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | {{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | ||
{{familytree/end}} | {{familytree/end}} | ||
<span style="font-size:85%">'''AF''': Atrial fibrillation; '''PMBC''': Percutaneous mitral ballon commissurotomy; '''TR''': Tricuspid regurgitation; '''S1''': First heart sound; '''P2''': Pulmonary component of second heart sound; '''EKG''': Electrocardiogram; '''TTE''': Transthoracic echocardiography; '''MS''': Mitral stenosis </span> <br> | |||
==Management== | ==Management== | ||
Line 104: | Line 105: | ||
{{familytree/end}} | {{familytree/end}} | ||
<span style="font-size:85%">'''MVA''': Mitral valve area; '''PMBC''': Percutaneous mitral ballon commissurotomy; '''PCWP''': Pulmonary capillary wedge pressure; '''ms''': milliseconds; '''NYHA''': New York Heart Association; '''AF''': Atrial fibrillation </span> <br> | <span style="font-size:85%">'''MVA''': Mitral valve area; '''PMBC''': Percutaneous mitral ballon commissurotomy; '''PCWP''': Pulmonary capillary wedge pressure; '''ms''': milliseconds; '''NYHA''': New York Heart Association; '''AF''': Atrial fibrillation </span> <br> | ||
==Do's== | ==Do's== |
Revision as of 23:41, 10 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Definition
Mitral stenosis refers to abnormal narrowing of mitral orifice which leads to obstruction of blood flow from left atrium to left ventricle and development of a pressure gradient between the two chambers.
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
Initial Evaluation
Shown below is an algorithm summarizing the approach to the initial evluation of mitral stenosis according to 2014 AHA/ACC guidelines for management of valvular heart disease.[2].
Characterize the symptoms: ❑ Exercise intolerance | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Examine the patient:
Head:
Neck: Chest:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical therapy ❑ Consider heart rate control in MS patients with:
❑ Consider anticoagulation therapy in MS patients with:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AF: Atrial fibrillation; PMBC: Percutaneous mitral ballon commissurotomy; TR: Tricuspid regurgitation; S1: First heart sound; P2: Pulmonary component of second heart sound; EKG: Electrocardiogram; TTE: Transthoracic echocardiography; MS: Mitral stenosis
Management
Shown below is an algorithm summarizing the approach to management of mitral stenosis according to 2014 AHA/ACC guidelines for management of valvular heart disease.[2]
❑Assess the presence of symptoms | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Symptomatic | Asymptomatic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Assess the severity of mitral stenosis | ❑ Assess the severity of mitral stenosis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Progressive ❑ MVA > 1.5 cm2 Pressure half time < 150 ms | Progressive ❑ MVA > 1.5 cm2 Pressure half time < 150 ms | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Assess if valve morphology is favorable for PMBC | ❑ Perform exercise testing | ❑ Assess if valve morphology is favorable for PMBC | ❑ Assess if valve morphology is favorable for PMBC | ❑ Monitor patient periodically | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ❑ Assess if PCWP > 25 mm Hg on exercise | Yes | No | No | Yes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Proceed with PMBC | ❑ Assess if patient is severely symptomatic (NYHA III/IV) ❑ Assess if the risk of surgery is high | ❑ Proceed with PMBC | ❑ Monitor patient periodically | ❑ Assess for the presence of new onset AF | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | AF present | No AF | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Proceed with PMBC | ❑ Proceed with mitral valve surgery | ❑ Proceed with PMBC | ❑ Monitor patient periodically | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MVA: Mitral valve area; PMBC: Percutaneous mitral ballon commissurotomy; PCWP: Pulmonary capillary wedge pressure; ms: milliseconds; NYHA: New York Heart Association; AF: Atrial fibrillation
Do's
Dont's
References
- ↑ Tadele, H.; Mekonnen, W.; Tefera, E. (2013). "Rheumatic mitral stenosis in Children: more accelerated course in sub-Saharan Patients". BMC Cardiovasc Disord. 13 (1): 95. doi:10.1186/1471-2261-13-95. PMID 24180350. Unknown parameter
|month=
ignored (help) - ↑ 2.0 2.1 Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA; et al. (2014). "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0000000000000029. PMID 24589852.